No Data
No Data
No Data
Mallinckrodt Presents Data on TERLIVAZ (Terlipressin) for Injection in Patients With Hepatorenal Syndrome (HRS) at the 2024 Digestive Disease Week (DDW)
10-Q: Quarterly report
Press Release: Mallinckrodt Plc Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides 2024 Guidance
Press Release: Mallinckrodt Plc Reports Fourth -11-
Mallinckrodt Plc: Expects to Incur Pre-Tax Charges, Exclusive of Impairments, of Approximately $15 Million, Plans to Recognize in 1Q 2024 and Remaining Amount Over FY24 and First Fiscal Quarter 2025
Mallinckrodt Plc: Evaluating Next Steps With Respect to StrataGraft, Which Could Include Pursuing a Sale, Out-License or Other Strategic Arrangement
No Data